Alexion Pharmaceuticals Given Overweight Rating at Barclays (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “overweight” rating reaffirmed by equities researchers at Barclays in a research report issued on Friday, Analyst Ratings Network reports. They currently have a $141.00 target price on the stock, up from their previous target price of $127.00. Barclays’ price objective points to a potential upside of 5.17% from the stock’s previous close.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 0.85% on Friday, hitting $135.21. The stock had a trading volume of 991,016 shares. Alexion Pharmaceuticals has a 1-year low of $81.82 and a 1-year high of $135.53. The stock has a 50-day moving average of $127.5 and a 200-day moving average of $115.1. The company has a market cap of $26.511 billion and a price-to-earnings ratio of 75.83.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.83 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter in the prior year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $3.04 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Nomura initiated coverage on shares of Alexion Pharmaceuticals in a research note to investors on Wednesday. They set a “buy” rating and a $150.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Alexion Pharmaceuticals from $130.00 to $150.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Alexion Pharmaceuticals from $138.00 to $161.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $130.59.
In other Alexion Pharmaceuticals news, CEO Leonard Bell sold 19,155 shares of Alexion Pharmaceuticals stock on the open market in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $134.98, for a total transaction of $2,585,541.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.